IP Verse

Purification Of Iduronate-2-Sulfatase - EP2867245

The patent EP2867245 was granted to Shire Human Genetic Therapies on Sep 12, 2018. The application was originally filed on Jun 28, 2013 under application number EP13809853A. The patent is currently recorded with a legal status of "Revoked".

EP2867245

SHIRE HUMAN GENETIC THERAPIES
Application Number
EP13809853A
Filing Date
Jun 28, 2013
Status
Revoked
Jun 24, 2024
Grant Date
Sep 12, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HGFJun 12, 2019HGFADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004229250
DESCRIPTIONWO2011163649
INTERNATIONAL-SEARCH-REPORTUS6096555
INTERNATIONAL-SEARCH-REPORTUS7323553
INTERNATIONAL-SEARCH-REPORTUS7541164
INTERNATIONAL-SEARCH-REPORTUS8128925
INTERNATIONAL-SEARCH-REPORTWO2011044542
OPPOSITIONEP2723369
OPPOSITIONKR101158673B
OPPOSITIONUS2004229250
OPPOSITIONWO2012177020
OPPOSITIONWO2014005014
OPPOSITIONWO2014005019
SEARCHUS5728381
SEARCHWO2004062592
SEARCHWO2011044542
SEARCHWO2012177020

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- BURROW, T ANDREW et al., "Review of the use of idursulfase in the treatment of mucopolysaccaridosis II", Biologics: Targets & Therapy, (20080000), vol. 2, pages 311 - 320, XP055140748-
OPPOSITION- "Elaprase ™ (idursulfase)", Approved Labeling / Application number: 125151/0, (20060718), pages 1 - 8-
OPPOSITION- FRALDI, ALEESANDRO et al., "SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies", Biochem Journal, (20070000), vol. 403, pages 305 - 312, XP002601852
OPPOSITION- MUENZER, JOSEPH et al., "A phase II/lll clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome", Genetics in Medicine, (20060000), vol. 8, no. 8, pages 465 - 473, XP055120247
OPPOSITION- CLARKE, LOME A., "Idursulfase for the treatment of mucopolysaccharidosis II", Expert opinion of Pharmacotherapy, (20080000), vol. 9, no. 2, pages 311 - 317, XP055346370
SEARCH- "SCIENTIFIC DISCUSSION", (20070101), URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000700/WC500023005.pdf, (20160108), XP055239719 [Y] 1-12 * p.4 (characterization)-p.5(specification) *-
SEARCH- MUENZER ET AL, "A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)", MOLECULAR GENETICS AND METABOLISM, ACADEMIC PRESS, AMSTERDAM, NL, (20070215), vol. 90, no. 3, doi:10.1016/J.YMGME.2006.09.001, ISSN 1096-7192, pages 329 - 337, XP005887987 [Y] 1-12 * paragraph on idursulfatase *
SEARCH- Qing-Hui Zhou ET AL, "Brain-Penetrating IgG-Iduronate 2-Sulfatase Fusion Protein for the Mouse", doi:10.1124/dmd.111.042903, (20120201), URL: http://dmd.aspetjournals.org/content/40/2/329.full.pdf#page=1&view=FitH, (20160107), XP055239284 [Y] 1-12 * material and methods *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents